Everything tagged "ipo" across the TickerSpark archives.
Gentherm Inc Common Stock When-Issued (NASDAQ: THRMV) is expected to list on 2026-09-28, but the price range has not been disclosed. The key question is whether investors treat this as a fresh IPO story or as a public-company transaction tied to Gentherm’s existing business. Shareholders should watch the deal structure and any pricing signal closely, since the setup is still missing the usual IPO terms.
Hotchkis & Wiley Mid-Cap Value Fund (HWMV) is expected to list on Nasdaq on 2026-09-24, with shares offered and price range not yet disclosed. This is an ETF class share listing tied to an existing mutual fund, not a traditional operating-company IPO. The setup favors investors who want active mid-cap value exposure, but shareholders should watch how the ETF trades versus NAV and whether the strategy can stand out in a crowded category.
ARC Group Securities Acquisition I Rights is expected to list on NASDAQ on 2026-09-24, but the price range has not been disclosed yet. This is a rights-bearing SPAC, so the real question is whether investors want the sponsor’s target-finding story or prefer to wait for a deal announcement.
Accelevation Holdings Corp. (NASDAQ: ACCV) is expected to list on 2026-09-30, and the IPO has priced at $18 per share after an earlier $20-$24 range. The company is a data center infrastructure builder tied to AI and cloud demand, but investors should watch customer concentration and whether backlog converts cleanly into revenue.
Oura Inc. is expected to list on NASDAQ on 2026-09-30 under ticker OURA, with shares priced at $40.00 to $44.00. The deal centers on a fast-growing smart-ring business with a sticky subscription model, but investors will need to weigh concentration, competition, and how much growth can hold after the IPO.
ADARx Pharmaceuticals is expected to list on NASDAQ on 2026-09-25, with shares priced in a $15.00 to $17.00 range. The company is offering 21,875,000 shares and has disclosed an implied market cap of $427,656,250. The setup favors investors who want late-stage RNA exposure, but the key watch item is whether the market gives credit to the pipeline before more clinical data arrives.
iShares Trust is expected to list on the NYSE on 2026-09-23 under the symbol AIBF, but the price range has not been disclosed. The setup is unusual: this is not a traditional operating-company IPO, but an ETF trust tied to ether exposure. Bull case: BlackRock’s iShares platform and regulated crypto access. Bear case: the trust’s economics, pricing, and float mechanics are not disclosed like a normal IPO.
newcleo plc Ordinary Shares is expected to list on NASDAQ on 2026-09-22, with the price range not yet disclosed. The deal is being pursued through a SPAC business combination with NewHold Investment Corp III under ticker NWCL. The setup favors investors who want exposure to advanced nuclear and fuel-cycle optionality, but the key watch item is whether the company can convert a long-dated technology story into a credible public-market path.
Bamboo Insurance Services, Inc. (NYSE: BMB) is expected to list on 2026-09-23 at a price range of $18.00 to $20.00 per share. The deal covers 35,000,000 shares and is structured as a secondary offering on the NYSE. The setup leans on fast growth and a capital-light insurance model, but shareholders should watch the fact that the company itself will not receive IPO proceeds and remains exposed to catastrophe, reinsurance, and regulatory risk.
Amaero Inc. (NASDAQ: AMRO) is expected to list on 2026-09-23 at a price range of 7.06. The IPO is set to bring a U.S.-based specialty powder metals maker to market as defense and aerospace supply chains keep favoring domestic sourcing. The bull case is strategic positioning; the bear case is that the company is still in a commercialization ramp with losses and financing needs.
Electra Therapeutics is expected to list on NASDAQ on 2026-09-18 in a $14.00 to $16.00 range. The company is offering 21,666,667 shares under ticker ETRA. The bull case is a first-in-class immune-cell depletion platform; the bear case is a clinical-stage biotech with no revenue and rising losses.
West Coast Community Bancorp is expected to list on NASDAQ on 2026-09-16, but the price range has not been disclosed. This is an uplisting from OTCQX via Form 10-12B, not a traditional capital-raising IPO. The setup favors a profitable community bank story, but investors should watch valuation, merger integration, and interest-rate sensitivity.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime